Targeted immunotherapies for hematologic malignancies

The overall goal of our research is to develop novel targeted immunotherapies for patients with hematologic malignancies. The group develops adoptive T cell therapies with native or engineered receptors and evaluates combinatorial strategies.

The objective is to efficiently target tumor cells, mitigate immunosuppressive tumor microenvironment factors, favor tumor-targeted migration and longevity of transferred T cells, control potential toxicities, identify novel personalized targets, and move developments to the clinic.

We also investigate mechanisms of toxicities or resistance to approved immunotherapies in translational studies.

Learn more

Image from Figure 4, illustrating BCMA internalization in myeloma cells after contact with CAR T cells.